|
Getting your Trinity Audio player ready...
|
SAN DIEGO, Calif., August 26, 2026 — Drug discovery can begin with 5,000 to 10,000 compounds, narrow to approximately 250 entering preclinical development, around five reaching clinical trials and ultimately produce just one approved medicine—highlighting why identifying weak drug candidates earlier can be critical to pharmaceutical R&D.
VivoSim Labs, Inc. (NASDAQ: VIVS) is targeting that decision-making process with its NAMkind™ 3D human liver and intestinal tissue models, designed to introduce human-relevant toxicity information earlier in drug development. VivoSim says its standard liver toxicology service can screen up to 200 compounds at multiple concentrations in approximately 17 days, potentially helping researchers determine which candidates should advance, undergo further optimization or be discontinued.
The opportunity could position VivoSim beyond traditional laboratory testing as a potential decision-support platform for pharmaceutical R&D, helping drug developers evaluate safety risks before committing substantially more capital to clinical development. VivoSim has reported approximately 91% predictive accuracy for liver toxicity, while its VitroSense™ AI platform has reported up to 96% predictive accuracy for drug-induced diarrhea.
Commercialization is beginning to advance through initial China programs and APAC distribution relationships, while VivoSim has reiterated guidance for 500%+ fiscal 2027 revenue growth from its NAM-based contract research business. The company also recently reported approximately $10.1 million in cash, supported in part by a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY) related to a previously divested drug program.
Alongside VivoSim Labs (NASDAQ: VIVS), investors are also watching Cre8 Enterprise Ltd. (NASDAQ: CRE), Volato Group, Inc. (NYSE American: SOAR), YY Group Holding Limited (NASDAQ: YYGH) and CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG), as actively traded small-cap stocks continue drawing market attention.
For investors, the developing VivoSim opportunity is increasingly straightforward: help pharmaceutical companies identify which drugs deserve additional development capital—and which do not—earlier in the process.
About VivoSim Labs
VivoSim Labs, Inc. (NASDAQ: VIVS) provides pharmaceutical and biotechnology companies with 3D human liver and intestinal tissue models for drug testing and toxicology using New Approach Methodologies (NAMs).
About The Street Reports
The Street Reports (TSR) a financial media platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.